by blocking androgen/AR, while activated alternative cell survival pathway through mitochondrial outer membrane proteins-mediated metabolism alternation and ROS elevation. These results implicated a novel mechanism in which PCa patients develop the resistance to anti-AR agents, and develop toward the androgen refractory stage. Novel roles of mitochondrial outer membrane proteins in the maintenance of androgen receptor protein stability, resistance to anti-androgen receptor agents and progression of prostate cancer.
or without comorbidities had better therapeutic efficacy after treatment than patients with more severe ED or comorbidities. The energy density of LESW treatment was closely related to its clinical outcome, especially on IIEF improvement. More frequent treatment or longer treatment course did not improve IIEF score. Conclusions: Studies of LESW for ED patients increased sharply in recent years. Most of these studies presented encouraging results, regardless of variation in LESW setup parameters or treatment protocols. These studies suggest that LESW could significantly improve the IIEF and EHS score of ED patients. The publication of robust evidence from additional randomized controlled trials and longerterm follow-up would provide us more confidence regarding utilization of LESW treatment for ED patients. Background: Anti-androgen/androgen receptor (AR) agents, as the first-line hormone therapy, have been commonly administrated in prostate cancer (PCa) patients. However, the response of patients to these agents is temporary, the diseases inevitably developed to the androgen-refractory stage, and lost the response to these agents. In this current study, we investigated the novel roles of mitochondrial outer membrane (TOM) proteins in the maintenance of AR protein stability, and the development of resistance to anti-AR agents through mitochondriamediated cell stress, and the activation of cell survival signaling pathways. Methods: The co-localization of AR and TOM proteins was observed by confocal microscopy and biochemical assays. The physical interaction between AR and TOM proteins and the interactive domains were identified by the co-immunoprecipitation. TOM genes were interfered by RNAi, and AR protein stability was assessed by confocal microscopy and immunoblot, and the AR transcription activity was tested by RT-PCR and luciferase reporter assay. The mitochondrial functions and intracellular metabolism were evaluated by a Seahorse Bioscience XFe analyzer, and ROS was tested by flow cytometry. The phenotype transition was identified by the cell morphology and specific biomarkers. The sensitivity of anti-AR agents was tested by the MTS assay and cell colony assays. Results: In AR-positive PCa cells, AR protein is located in mitochondria, and particularly interacts with TOM proteins through the LLXXL motifs at the C-terminal. Interfering one protein induced the degradation of another protein.
The knockdown of TOM protein impaired the AR protein stability, nuclear translocation and the transcription activity. Alternatively, the knockdown of AR or anti-AR agent Casodex impaired the stability of TOM proteins. Furthermore, the interference of TOM proteins drastically altered intracellular metabolism, especially in direction to weaken cell respiration and enhance aerobic glycolysis, so called the "Warburg effect". The consequence of the metabolic change contributed to the ROS elevation and the activation of PI3K/AKT pathway, cell survival and phenotype transition of PCa cells, and hence promoted cancer progression. Conclusions: In addition to HSP proteins, we, at the first time, reported that TOM proteins are alternative novel machine to maintain AR protein stability. Importantly, anti-AR agents obtained the therapeutic effects on PCa AB034. Investigation of RNA editing in urinary bladder cancer by transcriptome sequencing analysis
Song Wu
The Affiliated Luohu Hospital of Shenzhen University, Shenzhen Luohu Hospital Group, Shenzhen 518000, China Background: Bladder cancer can be imaged as a sustaining multistage course accumulating genetic and epigenetic changes. Moreover, plenty of studies uncovered that A-to-I RNA editing is an essential part of the growth of normal cells and involved in the variety of biological pathways. To better understand bladder cancer pathogenesis at the molecular level and to uncover novel tumor-initiating events, we integrate RNA-Seq data derived from 15 bladder cancer/normal paired samples. Methods: Fifteen bladder cancer/normal paired samples are obtained. We conduct transcriptome sequencing and on fifteen pairs of bladder cancer and matched adjacent tissues to identify RNA editing events. Results: Six tumor samples obtained are low-grade bladder cancer (superficial), nine high-grade bladder cancer (invasive). Statistical analyses reveal no significant alterations in the number of editing site between low-grade samples and high-grade samples. Further analysis uncovers that three non-synonymous edits exist in normal samples, and one of them, SON is a normal specific edit. Total 35 non-synonymous edits are identified in all the tumor samples. Further, tumor specific edited gene ANIZ1 is detected in two of the high-grade tumor samples (B59 and B71), suggesting that ANIZ1 may contribute to the progression of urinary bladder cancer. Conclusions: In this study, 15 bladder cancer/normal paired samples are included to investigate the difference between normal and tumor samples using a revised RNA editing identification method. Multiple RNA editing events are discovered in tumor and normal samples that indicate RNA editing plays a significant role in bladder cancer. Our study is the first one to research RNA editing events at exon genome level in bladder as we are known and it may offer a comprehensive view of the role of RNA editing on bladder cancer. 
